{
    "Trade/Device Name(s)": [
        "BD Phoenix Automated Microbiology System - GN Ceftolozane/tazobactam"
    ],
    "Submitter Information": "Becton, Dickinson, and Company",
    "510(k) Number": "K173252",
    "Predicate Device Reference 510(k) Number(s)": [
        "K132909"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "October 6, 2017",
    "Summary Letter Received Date": "October 10, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully automated short-term incubation cycle antimicrobial susceptibility system"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Ceftolozane/tazobactam",
        "Enterobacter cloacae",
        "Escherichia coli",
        "Klebsiella oxytoca",
        "Klebsiella pneumoniae",
        "Proteus mirabilis",
        "Pseudomonas aeruginosa",
        "Citrobacter koseri",
        "Morganella morganii",
        "Proteus vulgaris",
        "Providencia stuartii",
        "Serratia liquefaciens",
        "Serratia marcescens"
    ],
    "Specimen Type(s)": [
        "Isolate from pure culture"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix Automated Microbiology System",
        "BD Phoenix AP System"
    ],
    "Method(s)/Technology(ies)": [
        "Broth-based microdilution",
        "Redox indicator detection",
        "Automated bacterial identification and susceptibility testing"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Minimal inhibitory concentration (MIC) determination",
        "Automated identification (ID)"
    ],
    "Submission Type(s)": [
        "System",
        "Analyzer",
        "Panel",
        "Reagent",
        "Software",
        "Broth",
        "Indicator solution"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System GN Ceftolozane/tazobactam panel for in vitro quantitative antimicrobial susceptibility testing of Gram-negative bacteria using MIC determination",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by MIC for Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture, and most Gram-positive bacteria isolates belonging to Staphylococcus, Enterococcus, and Streptococcus genera",
    "fda_folder": "Microbiology"
}